Anti-angiogenic therapy for VEGF or VEGFR-2 can increase the transport of T cells to the tumor, thereby reducing immunosuppressive cytokines and regulatory T cells, which may help overcome resistance to checkpoint inhibitors’ medicinal properties (30). The gene discussed is KDR; the disease is neoplasm.